Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 14/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MARS1 | P56192 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL629222 | 0.99 | RPA1 (0.57) | RPA1SMN1; SMN2NR4A2PPP1CANPC1 | |
| SCHEMBL1986774 | 0.86 | RPA1 (0.77) | RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL13902218 | 0.80 | RPA1 (0.55) | RPA1SMN1; SMN2PPP1CANPC1MAPT | |
| SCHEMBL14626195 | 0.78 | MKNK1 (0.43) | RPA1NR4A2NPC1MAPTRAB9A | |
| SCHEMBL13912443 | 0.78 | RPA1 (0.44) | RPA1NPC1MAPTRAB9A | |
| SCHEMBL12278777 | 0.78 | NR4A2 (0.49) | SMN1; SMN2NR4A2NPC1MAPTRAB9A | |
| SCHEMBL8369157 | 0.77 | RPA1 (0.65) | RPA1SMN1; SMN2PPP1CA | |
| SCHEMBL14591226 | 0.77 | RPA1 (0.51) | RPA1MARS1 | |
| SCHEMBL13902212 | 0.77 | RPA1 (0.51) | RPA1MARS1 | |
| SCHEMBL629916 | 0.77 | NPC1 (0.53) | RPA1NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534680-B1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACO INVESTMENTS INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7501446-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501446-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501444-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501446-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501444-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501444-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2007-06-28 | — | — | US | disclosed |
| US-20060025454-A1 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| US-6960603-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1534279-A2 | PRENYLATION INHIBITORS CONTAINING DIMETHYL-CYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534680-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050004122-A1 | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use | DEVELOPMENT PARTNERS, LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040116425-A1 | Prenylation inhibitors and methods of their synthesis and use | X-CHEM, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040053970-A1 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004016741-A2 | PRENYLATION INHIBITORS CONTAINING DIMETHYL-CYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016592-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6649638-B1 | 5-Pyridin-3-yl-1H-pyrazole-3-carboxylic amide derivatives; cancer, restenosis, psoriasis, endometriosis, atherosclerosis, viral or yeast infection, and corneal neovascularization treatment | PPD DISCOVERY, INC. | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004122-A1 | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use | RCE1, GGPS1, FNTA | RPA1 3143/4885SMN1; SMN2 3523/4885NR4A2 3479/4885 |
| US-20060025454-A1 | Prenylation inhibitors and methods of their synthesis and use | FNTA, RCE1, GGPS1 | RPA1 3242/4885SMN1; SMN2 3780/4885NR4A2 3749/4885 |
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | FNTA, PTAR1, ZMPSTE24 | RPA1 3481/4885SMN1; SMN2 4110/4885NR4A2 2691/4885 |
| US-20040053970-A1 | Prenylation inhibitors and methods of their synthesis and use | FNTA, RCE1, GGPS1 | RPA1 3242/4885SMN1; SMN2 3780/4885NR4A2 3749/4885 |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | RCE1, GGPS1, FNTA | RPA1 3143/4885SMN1; SMN2 3523/4885NR4A2 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.